Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,700 | 4 | 66.8% |
| Food and Beverage | $2,809 | 67 | 21.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 2 | 11.5% |
| Travel and Lodging | $15.00 | 1 | 0.1% |
| Education | $8.45 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $8,460 | 6 | $0 (2020) |
| ABBVIE INC. | $1,856 | 30 | $0 (2024) |
| Gilead Sciences Inc | $1,035 | 2 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $915.69 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $275.33 | 15 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $208.19 | 2 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $201.60 | 2 | $0 (2018) |
| Lilly USA, LLC | $59.76 | 1 | $0 (2024) |
| Takeda Pharmaceuticals Puerto Rico LLC | $20.74 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $304.97 | 17 | ABBVIE INC. ($186.15) |
| 2023 | $1,234 | 10 | ABBVIE INC. ($1,165) |
| 2022 | $534.06 | 9 | ABBVIE INC. ($504.61) |
| 2021 | $14.98 | 1 | Janssen Pharmaceuticals, Inc ($14.98) |
| 2020 | $6,946 | 4 | Merck Sharp & Dohme Corporation ($6,800) |
| 2019 | $258.03 | 8 | Janssen Pharmaceuticals, Inc ($203.37) |
| 2018 | $575.79 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($220.67) |
| 2017 | $3,165 | 12 | Merck Sharp & Dohme Corporation ($1,660) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.32 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $59.76 | General |
| Category: Obesity | ||||||
| 10/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.32 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $59.06 | General |
| Category: Neuroscience | ||||||
| 09/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2024 | ABBVIE INC. | — | Education | In-kind items and services | $8.45 | General |
| 08/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 07/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.25 | General |
| Category: NEUROSCIENCE | ||||||
| 05/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.18 | General |
| Category: NEUROSCIENCE | ||||||
| 04/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.46 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.12 | General |
| Category: NEUROSCIENCE | ||||||
| 02/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: NEUROSCIENCE | ||||||
| 01/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.61 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.26 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Neuroscience | ||||||
| 08/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: NEUROSCIENCE | ||||||
| 07/13/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.66 | General |
| Category: NEUROSCIENCE | ||||||
| 05/17/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $101.60 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: NEUROSCIENCE | ||||||
| 03/29/2023 | ABBVIE INC. | VRAYLAR (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 38 | $2,507 | $1,508 |
| 2022 | 1 | 16 | 46 | $3,060 | $1,964 |
| 2021 | 1 | 20 | 50 | $3,400 | $2,169 |
| 2020 | 1 | 13 | 49 | $3,238 | $1,967 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 15 | 38 | $2,507 | $1,508 | 60.2% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 16 | 46 | $3,060 | $1,964 | 64.2% |
| 90832 | Psychotherapy, 30 minutes | Office | 2021 | 20 | 50 | $3,400 | $2,169 | 63.8% |
| 90832 | Psychotherapy, 30 minutes | Office | 2020 | 13 | 49 | $3,238 | $1,967 | 60.7% |
About Dr. Edgardo Prieto Agostini, MD
Dr. Edgardo Prieto Agostini, MD is a Psychiatry healthcare provider based in Coquas, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982765707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edgardo Prieto Agostini, MD has received a total of $13,033 in payments from pharmaceutical and medical device companies, with $304.97 received in 2024. These payments were reported across 75 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($8,700).
As a Medicare-enrolled provider, Prieto Agostini has provided services to 64 Medicare beneficiaries, totaling 183 services with total Medicare billing of $7,607. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Location Coquas, PR
- Active Since 12/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1982765707
Products in Payments
- JANUVIA (Drug) $6,800
- VRAYLAR (Drug) $1,848
- BELSOMRA (Drug) $1,660
- INVEGA SUSTENNA (Drug) $717.06
- Trintellix (Drug) $296.07
- AUSTEDO (Drug) $208.19
- LATUDA (Drug) $201.60
- SPRAVATO (Drug) $143.18
- ZEPBOUND (Drug) $59.76
- XARELTO (Drug) $55.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.